# A SHR0302 BA Study on Healthy Subjects

> **NCT06202612** · PHASE1 · COMPLETED · sponsor: **Jiangsu HengRui Medicine Co., Ltd.** · enrollment: 16 (actual)

## Conditions studied

- Autoimmune Diseases

## Interventions

- **DRUG:** SHR0302 quick release tablets
- **DRUG:** SHR0302 sustained-release tablets

## Key facts

- **NCT ID:** NCT06202612
- **Lead sponsor:** Jiangsu HengRui Medicine Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2024-01-16
- **Primary completion:** 2024-02-21
- **Final completion:** 2024-02-21
- **Target enrollment:** 16 (ACTUAL)
- **Last updated:** 2025-04-02


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06202612

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06202612, "A SHR0302 BA Study on Healthy Subjects". Retrieved via AI Analytics 2026-07-16 from https://api.ai-analytics.org/clinical/NCT06202612. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*